Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count.
Asian Pac J Allergy Immunol
;
2007 Jun-Sep; 25(2-3): 147-54
Article
in English
| IMSEAR
| ID: sea-37084
ABSTRACT
The objective of the study was to determine the predisposing factors and incidence of toxicity among AIDS patients treated with a nevirapine (NVP)-based regimen in clinical practice. A retrospective cohort study of representative samples of AIDS patients treated with a NVP-based regimen was performed. A total of 206 adult HIV/AIDS cases with median age (IQR) 33 years (range, 29-38 years), 51% male, treated between January 2004-December 2005, were included. Most (92.2%) of the patients were naïve to antiretroviral drug. The incidence of NVP toxicity was 1.09/100 person-months. The median onset time was 4 weeks post NVP initiation (2.57 weeks for skin toxicity and 12.43 weeks for hepatic toxicity). History of drug allergy and NVP toxicity were significantly associated (p = 0.006), as were sulfamethoxazole allergy and toxicity (p = 0.015). Regarding concomitant medication, concurrent anti-tuberculosis drugs significantly increased the risk of NVP associated liver toxicity (p = 0.001). Therefore, it is important to monitor adverse events from NVP, including liver function tests among HIV/AIDS patients with history of drug allergy, especially against sulfamethoxazole, and those concurrently treated with antituberculosis drugs.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Tuberculosis
/
Female
/
Humans
/
Male
/
HIV Infections
/
Causality
/
Retrospective Studies
/
Cohort Studies
/
HIV
/
AIDS-Related Opportunistic Infections
Type of study:
Etiology study
/
Incidence study
/
Observational study
/
Risk factors
Language:
English
Journal:
Asian Pac J Allergy Immunol
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS